115 related articles for article (PubMed ID: 38319154)
21. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
23. Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low.
Hu XE; Yang P; Chen S; Wei G; Yuan L; Yang Z; Gong L; He L; Yang L; Peng S; Dong Y; He X; Bao G
Breast Cancer Res; 2023 Mar; 25(1):34. PubMed ID: 36998014
[TBL] [Abstract][Full Text] [Related]
24. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer.
Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D
Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641
[TBL] [Abstract][Full Text] [Related]
25. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program.
Baré M; Torà N; Salas D; Sentís M; Ferrer J; Ibáñez J; Zubizarreta R; Sarriugarte G; Barata T; Domingo L; Castells X; Sala M
Breast Cancer Res Treat; 2015 Nov; 154(2):403-15. PubMed ID: 26531756
[TBL] [Abstract][Full Text] [Related]
26. Impact of breast cancer subtypes and patterns of metastasis on outcome.
Kast K; Link T; Friedrich K; Petzold A; Niedostatek A; Schoffer O; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Breast Cancer Res Treat; 2015 Apr; 150(3):621-9. PubMed ID: 25783184
[TBL] [Abstract][Full Text] [Related]
27. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.
Bae MS; Seo M; Kim KG; Park IA; Moon WK
Acta Radiol; 2015 Mar; 56(3):269-75. PubMed ID: 24558165
[TBL] [Abstract][Full Text] [Related]
28. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
Falck AK; Fernö M; Bendahl PO; Rydén L
World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
[TBL] [Abstract][Full Text] [Related]
29. Higher Detection Rates of Biologically Aggressive Breast Cancers in Mammography Screening than in the Biennial Interval.
Prange A; Bokhof B; Polzer P; Tio J; Radke I; Heidinger O; Heindel W; Weigel S
Rofo; 2019 Feb; 191(2):130-136. PubMed ID: 30103233
[TBL] [Abstract][Full Text] [Related]
30. The Association Between Clinicopathological Features and Molecular Markers in Bahraini Women With Breast Cancer.
AlZaman A; Ali E; Mohamad B; Islam M; AlZaman E; AlZaman Y
Gulf J Oncolog; 2020 Jan; 1(32):19-25. PubMed ID: 32342914
[TBL] [Abstract][Full Text] [Related]
31. Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With Breast Cancer.
Hassanzadeh Makoui M; Mobini M; Fekri S; Geranpayeh L; Moradi Tabriz H; Madjd Z; Kalantari E; Hosseini M; Hosseini M; Golsaz-Shirazi F; Jeddi-Tehrani M; Zarnani AH; Amiri MM; Shokri F
Clin Breast Cancer; 2024 Jan; 24(1):e9-e19.e9. PubMed ID: 37863762
[TBL] [Abstract][Full Text] [Related]
32. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.
Georgescu R; Boros M; Moncea D; Bauer O; Coros MF; Oprea A; Moldovan C; Podoleanu C; Stolnicu S
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):533-538. PubMed ID: 28099174
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
34. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
35. BREAST CANCER IN YOUNG WOMEN: PATHOLOGIC AND IMMUNOHISTOCHEMICAL FEATURES.
Erić I; Petek Erić A; Kristek J; Koprivčić I; Babić M
Acta Clin Croat; 2018 Sep; 57(3):497-502. PubMed ID: 31168183
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
37. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
39. Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China.
Xue C; Wang X; Peng R; Shi Y; Qin T; Liu D; Teng X; Wang S; Zhang L; Yuan Z
Cancer Sci; 2012 Sep; 103(9):1679-87. PubMed ID: 22625227
[TBL] [Abstract][Full Text] [Related]
40. Prognostic disparities in young patients based on breast cancer subtype: A population-based study from the SEER database.
Chen B; Zhang X; Liu Y; Wang C
Medicine (Baltimore); 2023 Mar; 102(13):e33416. PubMed ID: 37000095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
